Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 35,344 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Osteoarthritis
Interventions: Patient record review, Radiographs, and questionaires.; Other
Lead sponsor: Medacta USA; Industry
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Boise, Idaho

Conditions: Dry Eye, Dry Eye, Evaporative, Dry Eye Disease, Evaporative Dry Eye, Evaporative Dry Eye Disease, Kerato Conjunctivitis Sicca
Interventions: Miebo; Drug
Lead sponsor: Gordon Schanzlin New Vision; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Child Obesity
Interventions: Child Safety Control Intervention, Responsive Parenting Intervention; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: Not listed
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Hershey, Pennsylvania • State College, Pennsylvania

Conditions: Diarrhea
Interventions: ACE527, dmLT, CeraVacx placebo, H10407 challenge strain; Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 50 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Respimat, Tiotropium; Device · Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 3,991 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 57
States / cities: Birmingham, Alabama • Mobile, Alabama • Berkeley, California + 48 more

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions: Azacitidine, Durvalumab; Drug · Biological
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 12
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Gainesville, Florida + 9 more

Conditions: Type 2 Diabetes, Pregnancy
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Respiratory Syncytial Virus Prevention
Interventions: Ad26.RSV.PreF-based Vaccine; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years to 75 Years
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 13
States / cities: Athens, Alabama • Vestavia Hills, Alabama • Phoenix, Arizona + 8 more

Conditions: Pain, Chronic, Lumbar Radiculopathy, SCS
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Timeline: 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Polycystic Ovarian Syndrome, Obesity, Hepatic Steatosis
Interventions: oral glucose tolerance test, MRI of liver; Diagnostic Test
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 21 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Postoperative Pain
Interventions: Dexamethasone, Clonidine, Normal Saline; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 6 Months to 6 Years
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stroke, Ischemic, Stroke Hemorrhagic, Stroke, Cerebrovascular
Interventions: Reactive balance training with Neuromuscular Electrical Stimulation, Reactive balance training without Neuromuscular Electrical Stimulation; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 90 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Male Participants
Interventions: AG-881, [13C315N3]AG-881; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: HIV Infections
Interventions: Mycophenolate mofetil, Amdoxovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 11 more

Conditions: COVID-19, SARS-COV-2 Infection
Interventions: BNT162b2 Vaccine, Placebo; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 5,240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 196
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 148 more

Conditions: Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes, Familial Hypercholesterolemia
Interventions: Inclisiran, Evolocumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 8
States / cities: Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more

Conditions: Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v6 and v7, Stage II Bladder Cancer AJCC v6 and v7, Stage III Bladder Cancer AJCC v6 and v7
Interventions: Paclitaxel, Radiation Therapy, Trastuzumab; Drug · Radiation · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2022
U.S. locations: 180
States / cities: Mobile, Alabama • Anchorage, Alaska • Auburn, California + 115 more

Conditions: Alzheimer Disease, Healthy Aging
Interventions: BrightGo cognitive training, Standard of Care medication for early Alzheimer's Disease; Device · Drug
Lead sponsor: Bright Cloud International Corp; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: New Brunswick, New Jersey • North Brunswick, New Jersey

Conditions: Asthma
Interventions: CSJ117, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 21
States / cities: Bakersfield, California • Huntington Beach, California • Los Angeles, California + 16 more

Conditions: Kidney Transplant; Complications, Drug Interaction Food
Interventions: Grapefruit Juice; Dietary Supplement
Lead sponsor: Shirley M. Tsunoda; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Respiratory Control in Premature Infants
Interventions: Bedside Physiology study, Carotid Body Function Test, Room Air Challenge, Hypoxia Challenge Test, Effects of Nasal Cannula Flow, Magnetic Resonance Imaging, Echocardiogram, Blood Sample; Other · Diagnostic Test
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 1 Day to 28 Days
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Rumination Disorder
Interventions: CBT-RD; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 10 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Allergic Conjunctivitis
Interventions: RX-10045, Vehicle for RX-10045 arm; Drug
Lead sponsor: C.T. Development America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Erythema, Edema
Interventions: Miami w/o frag Personal lubricant; Device
Lead sponsor: Church & Dwight Company, Inc.; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Piscataway, New Jersey

Search by objective public record fields.

A Post-Market Retrospective Study on Revision Total Knee Arthroplasty Using Medacta GMK® Revision Prosthesis

Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers

Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) - Long Term Follow-Up

Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults

Tiotropium / Respimat One Year Study in COPD.

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

Fat Metabolism in Pregnancy and Neonatal Heart Function in Diabetes

A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years

Study on the Use of Intraoperative Neurophysiological Monitoring in Spinal Cord Stimulator Trials

Post-Prandial Liver Glucose Metabolism in PCOS

Dexamethasone or Clonidine as Adjuncts to Ropivacaine for Caudal Analgesia on Analgesia Duration in Children

The REACTplusNMES Trial: A Double-blinded RCT

A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881

A Study of DAPD Alone Versus DAPD Plus MMF for Treatment of HIV Infection

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Telerehabilitation Alzheimer's Disease Feasibility (TADF)

Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma

Drug Interaction With Envarsus XR and Grapefruit Juice

Prematurity-Related Ventilatory Control

A Pilot Study of Cognitive-Behavioral Therapy for Rumination Disorder (CBT-RD)

Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis

A Single-Center, Clinical Study to Evaluate the Safety of a Non-Fragranced Personal Lubricant in Healthy Female Subjects